Denali-Sanofi scraps mid-stage study for multiple sclerosis drug (updated)
Denali-Sanofi scraps mid-stage study for multiple sclerosis drug
Brief: Denali Therapeutics Says Informed By Sanofi That K2 Phase 2 Study Was Discontinued Based On Not Meeting Primary And Key Secondary Endpoints
Denali Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Denali Therapeutics Inc expected to post a loss of 63 cents a share - Earnings Preview
Brief: Denali Therapeutics Q2 EPS USD -0.59
U.S. RESEARCH ROUNDUP-Nvidia, Qualcomm, Tesla
U.S. RESEARCH ROUNDUP- Crescent Energy, Rockwell Automation, Transdigm Group
Denali Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Denali Therapeutics Q1 Basic EPS USD -0.68
Denali Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview
Brief: Denali Therapeutics Announces Completion Of Enrollment For Regimen G Evaluating eIF2B Agonist DNL343 In Phase 2/3 HEALEY ALS Platform Trial
Denali Therapeutics surges 30% after $500 mln PIPE financing
Denali Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Denali Therapeutics Q4 net income USD -119.473 million
Denali Therapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Autodesk, Hireright Holdings, Zebra Technologies
U.S. STOCKS ON THE MOVE-DT Midstream, Bio-Rad Labs, Copper miners
U.S. STOCKS ON THE MOVE-Super Micro Computer, Kinsale Capital, Kinnate Biopharma